Cynvenio’s technology for the molecular characterization of CTCs is unlocking the understanding of how mutations in blood-derived cells align with known cancer-associated mutations in the primary tumor.
Westlake Village, CA (PRWEB) October 11, 2012
Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research and individualized medicine via the molecular characterization of cancer, today announced that it will be presenting at CHI’s Emerging Molecular Diagnostics Partnering Forum, February 11-12, 2013 at the Moscone North Convention Center in San Francisco, CA. The Forum, which takes place during CHI's Molecular Med TRI-CON show, is designed to provide a showcase for promising young companies developing novel technologies and solutions for a range of diagnostic applications.
Dr. Paul Dempsey, Cynvenio’s Vice President of Bioengineering and Development, will present a talk entitled “Applications of a Liquid Biopsy Platform for Next-Generation Sequencing of CTC Populations”. In this presentation, Dr. Dempsey will discuss a proprietary method for rapid-turnaround analysis of CTCs to deliver actionable SNP sequence information that supports genomic research, accelerated clinical discoveries, longitudinal patient monitoring and the selection of targeted therapies.
“Cynvenio’s technology for the molecular characterization of CTCs is unlocking the understanding of how mutations in blood-derived cells align with known cancer-associated mutations in the primary tumor,” said Andre’ de Fusco, Cynvenio’s CEO. “Medical decisions will increasingly incorporate patient-specific genomic information developed in real time. The ability to easily sample patients’ blood, rapidly identify and then characterize the mutation-bearing cells of interest, is fast becoming the key to this model.”
About CHI’s Emerging Molecular Diagnostics Partnering Forum:
This event is a part of CHI's Molecular Med TRI-CON. Additional information can be found here: http://www.triconference.com/mmtc_content.aspx?id=116883
About Cynvenio Biosystems, Inc.:
Cynvenio has developed the LiquidBiopsy® platform, a high performance rare cell isolation system that enables the mutational profiling of circulating tumor cells obtained from a simple, minimally invasive blood draw. Cynvenio’s mission in oncology is to develop the tools for the early detection of disease, to enable longitudinal patient monitoring in support of better treatment decisions, and to facilitate the identification of genetically matched therapeutic solutions. Cynvenio is based in Westlake Village, California and is privately held. Find out more about the company here: http://www.cynvenio.com and http://www.liquidbiopsy.com.